RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 Kumar Jeetendra | September 8, 2020 TEL AVIV, Israel and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that opaganib1 demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. …
